Candel Therapeutics, Inc. Common Stock (CADL) Stock Price

CADLStock

$13.60+116.13%52W

Market Cap$1.04B

P/E—

PEG Ratio—

Div yield—

Beta-0.31

CADL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)108.58%

Price vs S&P 500 (4W)29.80%

VGM Score50.12

Book Value / Share (Quarterly)$1.88

P/TBV (Annual)0.59x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.67

Price vs S&P 500 (YTD)115.65%

Net Profit Margin (TTM)-15156.45%

EPS (TTM)$-0.98

10-Day Avg Trading Volume1.56M

EPS Excl Extra (TTM)$-0.98

EPS (Annual)$-1.74

ROI (Annual)-70.00%

Cash / Share (Quarterly)$2.66

ROA (Last FY)-51.63%

EBITD / Share (TTM)$-0.99

ROE (5Y Avg)-109.18%

Operating Margin (TTM)-28000.81%

Cash Flow / Share (Annual)$-0.71

P/B Ratio6.26x

P/B Ratio (Quarterly)2.60x

Net Income / Employee (Annual)$-1,003,200

EV / Revenue (TTM)5784.11x

Net Interest Coverage (TTM)-53.96x

ROA (TTM)-41.33%

EPS Incl Extra (Annual)$-1.74

Current Ratio (Annual)13.49x

Quick Ratio (Quarterly)27.63x

3-Month Avg Trading Volume1.87M

52-Week Price Return116.13%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.80

P/S Ratio (Annual)6916.71x

Asset Turnover (Annual)0.00x

52-Week High$13.82

EPS Excl Extra (Annual)$-1.74

CapEx CAGR (5Y)-16.84%

26-Week Price Return119.83%

Quick Ratio (Annual)13.31x

13-Week Price Return62.17%

Total Debt / Equity (Annual)0.91x

Current Ratio (Quarterly)28.05x

Enterprise Value$717.23M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-15035.20%

Cash / Share (Annual)$2.18

3-Month Return Std Dev64.03%

Net Income / Employee (TTM)$-989,500

ROE (Last FY)-83.19%

Net Interest Coverage (Annual)-68.11x

EPS Basic Excl Extra (Annual)$-1.74

Total Debt / Equity (Quarterly)0.34x

EPS Incl Extra (TTM)$-0.98

ROI (TTM)-46.54%

P/S Ratio (TTM)6972.49x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.65

Price vs S&P 500 (52W)97.82%

Year-to-Date Return127.61%

5-Day Price Return6.72%

EPS Normalized (Annual)$-1.74

ROA (5Y Avg)-50.92%

Net Profit Margin (Annual)-15035.20%

Month-to-Date Return28.47%

Cash Flow / Share (TTM)$-1.07

EBITD / Share (Annual)$-1.02

Operating Margin (Annual)-27777.60%

LT Debt / Equity (Annual)0.91x

ROI (5Y Avg)-66.33%

LT Debt / Equity (Quarterly)0.34x

EPS Basic Excl Extra (TTM)$-0.98

P/TBV (Quarterly)1.23x

P/B Ratio (Annual)5.97x

Pretax Margin (TTM)-15156.45%

Book Value / Share (Annual)$0.95

Price vs S&P 500 (13W)59.38%

Beta-0.31x

Revenue / Share (TTM)$0.00

ROE (TTM)-60.42%

52-Week Low$4.35

vGradeF

mGradeA

vgmGradeC

CADL Earnings Surprise History

Q2 25-0.20est. -0.17

Q3 25-0.23est. -0.17

Q4 25-0.29est. -0.23

Q1 26-0.14est. -0.33

Q2 26-0.36est. -0.23

CADL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.07

4.13

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CADLCandel Therapeutics, Inc. Common Stock	F	—	A	$13.60
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Candel Therapeutics, Inc. Common Stock

Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies designed to activate immune responses against cancer. The company operates two proprietary viral platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, positioning it in the emerging viral oncology sector.